Who are Misoprostol 400 Microgram Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): low dose peroral misoprostol, preoperative vaginal misoprostol, Intrauterine Misoprostol, misoprostol and cervical ripening.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/misoprostol-400-microgram-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Misoprostol 400 Microgram Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Misoprostol 400 Microgram Oral Tablet (Misoprostol 400 Microgram Oral Tablet) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin E1 analogue. Area: Gastroenterology; Obstetrics.

marketed Prostaglandin E1 analogue Prostaglandin E receptor (EP receptor) Gastroenterology; Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Misoprostol 400 Microgram Oral Tablet (Misoprostol 400 Microgram Oral Tablet) — Assuta Ashdod Hospital. Misoprostol is a prostaglandin E1 analogue that increases gastric mucus production and bicarbonate secretion while reducing gastric acid secretion.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Misoprostol 400 Microgram Oral Tablet TARGET	Misoprostol 400 Microgram Oral Tablet	Assuta Ashdod Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
low dose peroral misoprostol	low dose peroral misoprostol	University Medical Centre Ljubljana	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
preoperative vaginal misoprostol	preoperative vaginal misoprostol	Ain Shams Maternity Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
Intrauterine Misoprostol	Intrauterine Misoprostol	Department of Medical Services Ministry of Public Health of Thailand	phase 3	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
misoprostol and cervical ripening	misoprostol and cervical ripening	Ullevaal University Hospital	phase 3	Prostaglandin E1 analogue	Prostaglandin E receptor (EP1, EP3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin E1 analogue class)

Ain Shams Maternity Hospital · 1 drug in this class
Assuta Ashdod Hospital · 1 drug in this class
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class
Ullevaal University Hospital · 1 drug in this class
University Medical Centre Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Misoprostol 400 Microgram Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/misoprostol-400-microgram-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab